796738-67-5

Upstream product

• 55314-16-4 3-(N,N-dimethylamino)-1-(pyridin-3-yl)prop-2-en-1-one 
• 350-03-8 methyl-3-pyridylketone 
• 152460-07-6 1-(2-methyl-5-nitrophenyl)guanidine 
• 99-55-8 2-methyl-5-nitroaniline 
• 796738-68-6 N₁-amino(imino)methyl-4-methyl-3-nitroaniline nitrate 
• 55314-16-4 (E)-3-(dimethylamino)-1-(pyridin-3-yl)prop-2-en-1-one 

Downstream Products

• 571187-03-6 N,N-(4-methyl-3-aminophenyl)[4-(pyridin-3-yl)-pyrimidin-2-yl]amine 
• 1427066-92-9 methyl 4-({2-methyl-5-[4-(pyridin-3-yl)pyrimidin-2-ylamino]phenylimino}methyl)benzoate 
• 1427066-95-2 methyl 4-(2-methyl-3-{5-[4-(pyridin-3-yl)pyrimidin-2-ylamino]phenylamino}methyl)benzoate 

Relevant academic research and scientific papers

Facile synthesis of 2-phenylquinoline-4-carboxamide derivatives with variant structural features

The quinoline scaffold is an important class of heterocyclic compounds that possesses diverse chemotherapeutic activities. Thus, the 2-phenylquinoline-4- carboxamide derivatives containing a variety of moieties, such as 2-(2-furanyl)-1,3,4-oxadiazole, N-(2-methylphenyl)-4-(3-pyridinyl)-2- pyrimidinamine, 4,4′-bithiazole, purine, adamantine and resorcinol, have been designed and synthesized via Suzuki coupling, acid-base coupling and other typical reactions.

Functionally substituted Schiff bases in reduction reactions

Functionally substituted Schiff bases obtained by the condensation of nitroaniline, pyrimidinylaminoaniline, 5-aminoquinoline, 5-aminoquinaldine derivatives with 4-methylformylbenzoate were studied in the reactions of sodium borohydride with acidic activators, hydrazine hydrate in the presence of Raney nickel, Raney alloy in the presence of potassium hydroxide. By the reduction of azomethines new benzyl derivatives of aniline, quinolylamine, arylaminopyrimidine, and phenylenediamine were obtained.

Novel imatinib derivatives with altered specificity between Bcr-Abl and FMS, KIT, and PDGF receptors

Imatinib is a clinically important ATP analogue inhibitor that targets the tyrosine kinase domain of the intracellular Abl kinase and the PDGF receptor family. Imatinib has revolutionised the treatment of chronic myeloid leukaemia, which is caused by the oncogene Bcr-Abl and certain solid tumours that harbor oncogenic mutations of the PDGF receptor family. As a leading kinase inhibitor, imatinib also provides an excellent model system to investigate how changes in drug design impact biological activity, which is an important consideration for rational drug design. Herein we report a new series of imatinib derivatives that in general have greater activity against the family of PDGF receptors and poorer activity against Abl, as a result of modifications of the phenyl and N-methylpiperazine rings. These new compounds provide a platform for further drug development against the therapeutically important PDGF receptor family and they also provide insight into the engineering of drugs with altered biological activity.

N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF

The present invention relates to an N-phenyl-2-pyrimidine-amine derivative showing a superior effect on tumor, lung cancer, gastric cancer, etc. of warm-blooded animals and its salt. The present invention also relates to a process for preparing the compound and a pharmaceutical composition for the prevention and treatment of such diseases as tumor, lung cancer, gastric cancer, etc., which comprises the compound as an active ingredient.

N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF

The present invention relates to an N-Phenyl-2-pyrimidine-aminine derivative showing a superior effect on lung cancer, gastric cancer, colon cancer, pancreatic cancer, hepatoma, prostatic cancer, breast cancer, chronic or accute leukemia, hematologic malignancy, encephalophyma, bladder cancer, rectal cancer or cervical cancer, etc. of warm blooded animals and its salt. The present invention also relates to a process for preparing the compound, and to a pharmaceutical composition for the treatment of the above various disease, which comprises an effective amount of the compound as an active ingredient together with pharmaceutically acceptable inert carriers.

N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof

The present invention relates to an N-phenyl-2-pyrimidine-amine derivative showing a superior effect on lung cancer, gastric cancer, colon cancer, pancreatic cancer, hepatoma, prostatic cancer, breast cancer, chronic or acute leukemia, hematologic malignancy, encephalophyma, bladder cancer, rectal cancer, or cervical cancer, etc. of warm-blooded animals and its salt. The present invention also relates to a process for preparing the compound, and to a pharmaceutical composition for the treatment of the above various diseases, which comprises an effective amount of the compound as an active ingredient together with pharmaceutically acceptable inert carriers.